Division of Cardiology

Bibliography 2005

2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |

Publications

Original Articles

1. Adams KF Jr, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005;46:497-504.

2. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M. Digoxin and reduction in mortality and hospitalization inheart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2005;27:178-86

3. Al-khatib SM, Sanders GD, Mark DB, Lee KL, Bardy GH, Bigger JT, Buxton AE, Connolly S, Kadish A, Moss A, Feldman AM, Ellenbogen KA, Singh S, Califf RM; Expert panel participating in a Duke Clinical Research Institute-sponsored conference. Implant-able cardioverter defibrill-ators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. Am Heart J 2005;149:1020-1034.

4. Ardehali, H. Cytoprotective channels in mitochondria. J Bioenerg Biomembr. 2005;37:171-177.

5. Ardehali, H., Dong, P., Macahmer, C., Marban, E. Removal of the mitochondrial targeting signal leads to targeting of the mitochondrial membrane proteins to the secretory path-way. Biochem Biophys Res Commun 2005;338:1143-1151.

6. Ardehali, H., Howard, D., Hariri, R., Qasim, A., Hare, J., Baughman, K. L., Kasper, K. K. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005;150:459-463.

7. Ardehali, H., Kapser, E., Baughman, K. Approach to the patient with cardiomyopathy: whom to biopsy. Am. Heart J 2005;149:7-12.

8. Ardehali, H., O’Rourke, B. Mitochondrial KATP channels in cell survival and death. J Mol Cell Cardiology 2005;39:-7-16.

9. Ardehali, H., O’Rourke, B, Marban, E. Cardioprotective role of the mitochondrial ATP-binding cassette protein-1. Circ Res 2005;97:740-742.

10. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:47G-58G

11. Bax JJ, Bonow RO, Tschoepe D, Inzucchi SE, Barrett EJ. Early detection of coronary heart disease in diabetic patients without symptoms of coronary artery disease: implications for expanded use of myocardial perfusion imaging. Br J Diabetes Vasc Dis 2005;5:283-288

12. Bello D, Fieno D, Kim R, Pereles S, Passman R, Song G, Kadish A, Goldberger J. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005;104-108

13. Bennett CL, Nebeker JR, Lyons EA, Samore, MH, Feldman MD, McKoy JM, Carson KR, Belknap SM, Trifilio SM, Schumock GT, Yarnold PR, Davidson CJ, Evens AM, Kuzel TM, Parada JP, Cournoyer D, West DP, Sartor O, Tallman MS, Raisch DW. The Research on Adverse Drug Events and Reports (RADAR) Project. JAMA 2005;293:2131-2141

14. Berger JS. Slater JN. Sherman W. Green SJ. Sanborn TA. Brown DL. Impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes and long-term survival following percutaneous coronary rotational atherectomy. J Thrombosis Thrombolysis 2005;19:47-54

15. Blomeier H, Stone NJ. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005;25:233-234.

16. Bonow RO. Molecular beacons illuminate subcellular events. Circulation 2005;111:1730-1732

17. Bonow RO. Bridging funding for young investigators. J Am Coll Cardiol 2005;46:15A-18A

18. Bonow RO, Bennett S, Ganiats TG, Hlatky MA, Konstam MA, Lambrew CT, Normand ST, Pina IL, Radford MJ, Smith AL, Stevenson LW. ACC/AHA clinical peformance measures for adults with chronic heart failure. A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol 2005;46:1144-1178 and Circulation 2005; 112:1853-1887

19. Bonow RO, Cheitlin MD, Crawford MH, Douglas, PS. Task Force 3. Valvular Heart Disease. Bethesda Confer-ence 36: Recommendations for determining eligibility for competition in athletes with cardiovascular disease. J Am Coll Cardiol 2005;45:1334-1340

20. Bonow RO, Grant AO, Jacobs AK. The cardiovascular state of the union: confronting healthcare disparities. Circulation 2005;111:1205-1207

21. Bonow RO, Roberts WC. Robert Ogden Bonow, MD: a conversation with the editor on valvular heart disease and indications for operative intervention. Baylor Univ Med Ctr Proc 2005;18:56-64

22. Caira F, Bonow RO, Rajamannan NM. Atorvastatin improves cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol 2005;41:631-633

23. Dang NC, Aboodi MS, Sakaguchi T, Wasserman HS, Argenziano M, Cosgrove DM, Rosengart TK, Feldman T , Block PC, Oz MC. Surgical revision after percutaneous mitral valve repair with a clip: initial multi-center experience. Ann Thor Surg 2005;80:2338-2342

24. Decker RS, Decker ML, Kulikovskaya I, Nakamura S, Lee DC, Harris K, Klocke FJ, Winegrad S. Myosin binding protein-C phosphorylation, myofibril structure, and contractile function during low-flow ischemia. Circulation 2005;111:906-912

25. De Luca L, Gheorghiade M, Bonow RO. Introduction. Am J Cardiol 2005;96 Suppl 1:1-2.

26. De Luca L, Sardella G, Davidson CJ, De Persio G, Beraldi M, Tommasone T, Mancone M, Nguyen BL, Agati L, Gheorghiade M, Fedele F. Impact of intracoronary aspiration thrombectomy during primary angioplasty on left ventricular remodelling in patients with anterior ST-elevation myocardial infarction. Heart 2005 (Online)

27. Dzavik V, Sleeper LA, Picard MH, Sanborn TA, Lowe AM, Gin K, Saucedo J, Webb JG, Menon V, Slater JN, Hochman JS. Outcome of patients aged 75 years or older in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? Am Heart J 2005;149:1128-1134

28. The ESCAPE Investigators (Gheorghiade M) Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness. JAMA. 2005;294:1625-1633

29. Feldman T, Wasserman HS, Herrmann HC, Gray W, Block PC, Whiltlow PL, St.Goar F, Rodriguez L, Silvestry F, Schwartyz A, Sanborn TA, Condado JA, Foster E. Percutaneous mitral valve repair using the edge-to-edge technique: 6 month resultsof the EVEREST phase I clinical trial. J Am Coll Cardiol 2005;46:2134-2140

30. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005;293:1501-1508

31. Fletcher B, Berra K, Ades P, Braun LT, Burke LE, Durstine JL, Fair JM, Fletcher GF, Goff D, Hayman LL, Hiatt WR, Miller NH, Krauss R, Kris-Etherton P, Stone N, Wilterdink J, Winston M; Managing abnormal blood lipids: a collaborative approach. Circulation 2005;112:3184-3209.

32. Fox CS, Evans JC, Larson MG, Lloyd-Jones DM, O’Donnell CJ, Sorlie PD, Manolio TA, Kannel WB, Levy D. A comparison of death certificate out-of-hospital coronary heart disease death with physician-adjudicated sudden cardiac death. Am J Cardiol 2005;95:856-859.

33. Gheorghiade M. Uso dei beta-blocanti nei pazienti con syndrome metabolico. Aggiornamento Medico 2005;29: 126-131.

34. Gheorghiade M. Profilo clinico farmacologico di carvedilolo. Il Cardiologo 2005;4:Suppl 4.1-17.

35. Gheorghiade M, De Luca L, Bonow RO. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am J Cardiol 2005;96:3L-9L. 36. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Mtra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96:11G-17G 37. Gheorghiade M, Filippatos G. Reassessing treatment of acute heart failure syndromes: The ADHERE registry. Eur Heart J 2005;27:Suppl. 8:B13-B19.38. Gheorghiade M, Gattis Stough W, Adams KF Jr, Jaffe AS, Hasselblad V, O'Connor CM. The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). Am J Cardiol 2005;96:18G-25G.

39. Gheorghiade M, Mebazaa A. Introduction to acute heart failure syndromes. Am J Cardiol 2005;96:1G-4G.

40. Gheorghiade M, Mebazaa A. The challenge of acute heart failure syndromes. Am J Cardiol 2005;96:68G-73G.

41. Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 2005;11:260-269

42. Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol 2005;96:68G-73G.

43. Gheorghiade M, Zannad F. Modern management of acute heart failure syndromes. Eur Heart J 2005;27: Suppl. 8:B3-B7.

44. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM,Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L; International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005112:3958-68

45. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol2005;46:1785-91.

46. Hamilton AJ, Kim H, Nagaraj A, Mun JH, Yan LL, Roth SI, McPherson DD, Chandran KB. Regional material property alterations in porcine femoral arteries with atheroma development. J Biomechanics 2005;38:2354-2364.

47. Huang MY, Kktar T, Sakata Y, Salinger MH, Frohlich TG, McDonough TJ, Koenigsberg DI, Kogan A, Tommaso CI, Sanborn TA, Feldman T. Frequency of off label drug eluting stent use in clinical practice. Am J Cardiol 2005;96:134H

48. Ilkhanoff L, O’Donnell CJ, Camargo CA, O’Halloran TD, Giugliano RP, Lloyd-Jones DM. The TIMI risk index predicts in-hospital and long-term mortality across the spectrum of acute coronary syndromes. Am J Cardiol 2005;96:773-777.

49. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen A, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Melanson SF, Sluss PM, Lee-Lewandrowski E, and Lewandrowski KB. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-954.

50. Kadish AH. Prophylactic defibrilator implantation: toward an evidence based approach. N Engl J Med 2005;352:285-287.

51. Kadish A. Should every patient with left-ventricular systolic dysfunction receive implantable cardioverter-defibrillators? Nat Clin Pract Cardiovasc Med 2005;2;188-189

52. Kadish A, Mehra M. Heart Failure Devices: Implantable cardioverter-defibrillators and biventricular pacing therapy. Circulation. 2005;111:3327-3335

53. Kadish A. Defibrillation in the Brugada syndrome. J Cardiovasc Electrrophysiol. 2005;16:267-8.

54. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M. OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111:2454-2460.

55. Klocke, F. J. Resting myocardial blood flow in hypocontractile myocardium: resolving the controversy. Circulation 2005;112:3222-3224

56. Krauser D, Lloyd-Jones DM, Chae CU, Januzzi JL Jr. Effect of body-mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005;149:744-750.

57. Kupersmith J, Sung N, Yates J, Genel M, Slavkin H, Bonow RO, Sherwood L, Catanese V, Reame N, Tilson H, Reece EA. Creating a new structure for research on healthcare effectiveness. J Invest Med 2005;53:67-72

58. Leon MB, Kornowski R, Downey WE, Weisz G, Baim, DS, Bonow RO, Hendel RC, Cohen DJ, Gervino E, Laham R, Lembo NJ, Moses JW, Kuntz RE. A blinded randomized placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol 2005;46: 1812-1819

59. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005;294:466-472.

60. Lloyd-Jones DM, Leip EP, Larson MG, Vasan RS, Levy D. Novel approach to examining first cardiovascular events after hypertension onset. Hypertension 2005;45:39-45

61. Lloyd-Jones DM, Redberg RF. Risk stratification in asymptomatic patients. Patient Care 2005;39:39-45.

62. Lloyd-Jones DM, Sutton-Tyrrell K, Patel AS, Matthews KA, Pasternak RC, Everson-Rose SA, Scuteri A, Chae CU. Ethnic variation in hypertension in premenopausal and perimenopausal women: Study of Women’s Health Across the Nation. Hypertension 2005;46:689-695.

63. Makkena B, Salti H, Subramaniam M, Thennapan S, Bonow RH, Caira F, Bonow RO, Spelsberg TC, Rajamannan NM. Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve. J Am Coll Cardiol 2005;45:631-633.

64. McPherson, DD. Circulatory dysfunction in NAFLD: which is first, which is last, and what do we do in between? Hepatology 2005;42:270-272

65. Murabito JM, Pencina M, Nam BH, D’Agostino RB, Wang TJ, Lloyd-Jones DM, Wilson PWF, O’Donnell CJ. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: The Framingham Offspring Study. JAMA 2005;294:3117-3123.

66. Nagaraj A, Kim H, Hamilton AJ, Mun JH, Smulevitz B, Kane BJ, Yan LL, Roth SI, McPherson DD, Chandran KB. Porcine carotid arterial material property alterations with induced atheroma: an in vivo study. Med Eng Phys 2005; 27:147-156.

67. O'Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005;11:200-205.

68. Orlandi C, Zimmer CA, Gheorghiade M. Role of vasopressin antagonists in the management of acute decompensated heart failure. Curr Heart Fail Rep 2005;2:131-139.

69. Passman R, Kadish A. Rate control versus rhythm control: choose your poison. Am Heart J 2005;149;957-959

70. Passman RS, Gingold DS, Amar D, Lloyd-Jones DM, Bennett CL, Zhang H, Rusch VW. Prediction rule for atrial fibrillation after major non-cardiac thoracic surgery. Ann Thorac Surg 2005;79:1698-1703.

71. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J; EPHESUS Investigators. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-31.

72. Rajamannan NM. Medical and surgical management of aortic stenosis, calcific aortic stenosis:medical and surgical management in the elderly. Curr Treat Options Cardiovasc Med. 2005;7:437-442

73. Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev C, Sebo TJ, Rosengart TK, Orszulak TC, Edwards WD, McCarthy PM, Bonow RO, Spelsberg T. Calcified rheumatic valve angiogenesis is associated with vascular endothelial growth factor expression and osteo-blast-like bone formation. Circulation 2005;111:3296-3301

74. Rajamannan NM, Subramanium M, Stock S, Caira. F, Spelsberg TC, Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005;112(Suppl):I229-234.

75. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell J, Singh R, Bonow RO, Spelsberg TC. Atorvastatin inhibits aortic valve calcification and enhances nitric oxide synthase production in the hypercholesterolemic aortic valve. Heart 2005;91: 806-810

76. Rosenfield KM, Cowley MJ, Jaff MR, Ouriel K, Gray W, Cates CU, Feldman T, Babb JD, Gallagher A, Green R, Kent KC, Roubin GS, Weiner BH, White CW. SCAI/SVMB/SVS clinical competence statement on carotid stenting: training and credentialing for carotid stenting: multispecialty consensus recommendations. Cathet Cardiovasc Intervent 2005;64:1-11

77. Rosengart TK, Sweet J, Finnin EB, Wolfe P, Cashy J, Hahn E, Marymount J, Sanborn TA. Neurocognitive functioning in patients undergoing coronary artery bypass graft surgery or percutaneous coronary intervention: evidence of impairment before intervention compared with normal controls. Ann Thorac Surg 2005;80:1327-1335

78. Rosenson RS, Lloyd-Jones DM. Critical appraisal of revised cholesterol guidelines for the very high risk patient. Expt Rev Cardiovasc Ther 2005;3:173-178.

79. Sakata Y, Sayed Y, Salinger MH, Feldman T. Percutaneous balloon aortic valvuloplasty: antegrade transseptal vs. conventional retrogradetransarterial approach. Cathet Cardiovasc Intervent 2005;64:314-321

80. Saleem M, Burkett S, Passman R, Dibs S, Engelstein E, Kadish A, Goldberger J. New simplified technique for 3D mapping and ablation of right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol 2005;28:397-403

81. Sanborn T. Percutaneous mitral valve repair. J Heart Disease 2005;4:60

82. Sjaastad, I, JA Birkeland, Ferrier G, Howlett S, Skomedal T, Bjornerheim R, Wasserstrom JA, Sejersted O. Defective excitation-contraction coupling in hearts of rats with congestive heart failure. Acta Phys Scand 2005;184:45-58.

83. Smith SC, Clark LT, Cooper RS, Daniels SR, Kumanyika SK, Ofili E, Quinones MA, Sanchez EJ, Saunders E, Tiukinhoy SD. Discovering the full spectrum of cardiovascular disease: the Minority Health Summit 2003. Report of the Obesity, Metabolic Syndrome, and Hyperten-sion Writing Group. Circulation 2005;111:e134-e139.

84. Stough WG, O’Connor CM, Gheorghiade M. Overview of current noninodilator therapies for acute heart failure syndromes. Am J Cardiol 2005;96:41G-6G.

85. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III Update: Adjustments and Options. Am J Cardiol. 2005;96: 53-59.

86. Stone NJ, Saxon D. Approach to treatment of the patient with metabolic syndrome: lifestyle therapy. Am J Cardiol. 2005;96:15-21.

87. Stone P, Lloyd-Jones DM, Johnstone M, Carlson W, Rubenstein J, Andrews T, Creager M, Frei B, Sopko G, MacCallum G, Cole H, Kinlay S, Orav J, Selwyn A. Effect of intensive lipid-lowering, with or without antioxidant vitamins, versus moderate lipid-lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study. Circulation 2005;111:1747-1755.

88. Sutton-Tyrrell K, Wildman RP, Matthews KA, Chae C, Lasley BL, Brockwell S, Pasternak RC, Lloyd-Jones DM, Sowers MF, Torréns JI. Sex hormone binding globulin and the free androgen index are related to cardiovascular risk factors in multi-ethnic pre and peri-menopausal women enrolled in the Study of Women's Health Across the Nation (SWAN). Circulation 2005;111:1242-1249.

89. Vassiliades TA Jr., Block PC, Cohn LH, Adams DH, Borer JS, Feldman T,Holmes DR, Laskey WK, Lytle BW, Mack MJ, Williams DO. The clinical development of percutaneous heart valve technology: an interdisci-plinary position statement of the Society of Thoracic Surgeons, the American Association for Thoracic Surgery, the American College of Cardiology and the Society of Cardiovascular Angiography and Intervention. Cathet Cardiovasc Interenr 2005;65:73-79, Ann Thorac Surg 2005;79:1812-1818, J Am Coll Cardiol 2005;45:1554-1560

90. Wasserstrom JA, Aistrup, GL. Digitalis: new actions for an old drug. Amer J Physiol 2005;289:H1781-H1793.

91. White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, Wong CK, Stewart JT, Aylward PE, Wong SC, Hochman JS. Comparison of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting and Acute Myocardial Infarction Complicated by Cardiogenic Shock Results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. Circulation 2005;112:1992-2001

92. Yancy CW, Benjamin EJ, Bonow RO. Discovering the full spectrum of cardiovascular disease: the Minority Health Summit 2003. Executive summary. Circulation 2005;111: 339-1349

Books and Symposia

1. Fuster V, Bonow RO. How to Become a Cardiovascular Investigator, J Am Coll Cardiol 2005;46:A1-A70

2. Miller AJ. Chest Pain: When & When not to Worry. Pass Christian, Mississippi, Self-Help Books, LLC, 2005

3. Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 7th edition. Philadelphia: Elsevier Science 2005

Book Chapters

1. Adams K, Gheorghiade M. Vasopressin antagonists. In: O’connor C, Stough W, Gheorghiade M, Adams K, eds. Managing Acute Decompensated Heart Failure. Taylor & Francis 2005; pp497-503.

2. Beohar N, Ricciardi MJ, Davidson CJ. Cardiac catheterization. In: Rosendorff C, ed. Essential Cardiology. Philadelphia: WB Saunders 2005.

3. Bonow RO, Braunwald E. Valvular heart disease. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Heart Disease: A Textbook of Cardiovascular Medicine. 7th edition. Philadelphia: Elsevier Science 2004, pp 1553-1621.

4. Brodsky AM, Fintel DJ. Atrial fibrillation. In: Conn’s Current Therapy; WB Saunders, 2005

5. Califf RC, Bonow RO. Foreward. In: O’connor C, Stough W, Gheorghiade M, Adams K, eds. Managing Acute De-compensated Heart Failure. Taylor & Francis 2005; pp v

6. Chandran KB, Kim H, McPherson DD. Material property alterations with early atheroma in an animal model. In: Holzapfel GA, Ogden RW, eds. Mechanics of Biological Tissue, IUTAM Proceedings 2005. Springer, pp 245-256.

7. Cotter G., Stough W., Felker G., Velazquez E., Hernandez A, Rogers J, Gheorghiade M, Adams K, O’Connor C. Acute heart failure: nomenclature, pathophysiology, and outcome measures. In: O’connor C, Stough W, Gheorghiade M, Adams K, eds. Managing Acute Decompensated Heart Failure. Taylor & Francis 2005; pp 19-39.

8. Davidson CJ, Bonow RO. Cardiac catheterization. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Heart Disease: A Textbook of Cardiovascular Medicine. 7th edition. Philadelphia: Elsevier Science 2004; pp 395-422.

9. Emanuel LL, Bonow RO. Care of patients with end-stage heart disease. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Heart Disease: A Textbook of Cardiovascular Medicine. 7th edition. Philadelphia: Elsevier Science 2004, pp 53-61.

10. Feldman T. Percutaneous therapies for valvular heart disease. In: Baim DS, Grossman W, eds. Grossman's Cardiac Catheterization, Angiography & Intervention, 7th Edition. Philadpelphia: Lippincott Williams & Wilkins, 2005, p 543-561.

11. Feldman T, Grossman W: Profiles in valvular heart disease. In: Baim DS, Grossman W, eds. Grossman's Cardiac Catheterization, Angiography & Intervention, 7th Edition. Philadpelphia: Lippincott Williams & Wilkins, 2005, pp 637-659.

12. Feldman T, Sanborn TA, O'Neill WW. Balloon aortic and pulmonicvalvuloplasty. In: Herrmann HC, ed. Contemporary Cardiology: Interventional Cardiology-Percutaneous Noncoronary Intervention. Humana Press, 2005, p 29-48.

13. Felker G, Gheorghiade M. Inotropes and other new ther-apies for acute heart failure. In: O’connor C, Stough W, Gheorghiade M, Adams K, eds. Managing Acute Decomp-ensated Heart Failure. Taylor & Francis 2005; pp 339-349

14. St. Goar FG, Fann JI, Feldman TE, Block PC, Herrmann HC. Percutaneous mitral valve repair with the edge-to-edge technique. In: Herrmann HC, ed. Contemporary Cardiology: Interventional Cardiology-Percutaneous Noncoronary Intervention. Humana Press, 2005, p 87-95.

15. Stone, NJ. Strategies for treating abnormal lipid profiles with drugs. In: Grundy S, ed. Atlas of Atherosclerosis, Risk Factors and Treatment. 4th Edition, Current Medicine, Philadelphia, pp 143-166.

16. Stone NJ. Approach to hyperlipidemia. In: Alpert J, ed. Cardiology for the Primary Care Physician, 4th edition, Philadelphia, 2005.

17. Udelson JE, Dilsizian V, Bonow RO. Nuclear cardiology. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Heart Disease:A Textbook of Cardiovascular Medicine. 7th edition. Philadelphia: Elsevier Science 2004, pp 287-331

Abstracts

1. Abraham W, Albert N, Stough W, Gheorghiade M, Greenberg B, O’Connor C, Sun J, Yancy C, Young J, Fonarow G. Predictors of in-hospital mortality in patients hospitalized with heart failure: an analysis of 48,612 hospitalizations from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patietns with Heart Failure. Circulation 2005;112:II-2429.

2. Ahmed A, Rich M, Gheorghiade M. Low-dose digoxin reduces mortality and hospitalization in chronic heart failure: a comprehensive post-hoc analysis of the Digitalis Investigation Group (DIG) Trial. Circulation 2005;112:II-3030.

3. Aistrup GL, Kelly JE, Sysman-Wolpin I, Kapur S, Wasserstrom JA. Ca2+ alternans takes three distinct forms in left ventricular myocardium. Circulation 2005;112:II-76.

4. Ardehali, H., Chen, Z., Ko, Y., Mejia-Alvarez, R., Marbán, E. Macromolecular protein complex in the mitochondrial inner membrane with ATP-sensitive K+ channel activity. Biophys J 2005;88:948

5. Ardehali, H., Dong, P., Machamer, C., Marban, E. Removal of the mitochondrial targeting signal leads to targeting of the mitochondrial membrane proteins to the secretory pathway. Biophys J 2005;88:1267

6. Ardehali, H, Jones, S, Marban, E. Integration of the respiratory and apoptotic pathways in the mitochondria. Circulation 2005;112:832.

7. Ardehali, H., O’Rourke, B, Marban, E. Cardioprotective role of the mitochondrial ATP-binding cassette protein-1. Circ Research 2005;97:e22.

8. Ardehali, H., O’Rourke, B, Marban, E. Cardioprotective role of the mitochondrial ATP-binding cassette protein-1. Circulation 2005;112:835

9. Arora R, Ng J, Ulphani J, Shade G, Morris A, Gordon D, Harris C, Goldberger J, Kadish AH. (P3-18) Autonomic profile of the pulmonary veins. Heart Rhythm 2005:2:S180.

10. Bello D, Kaushal R, Fieno D, Radin M, Shaoulian E, Narula J, Goldberger J, Kadish A, Shivkumar K. Cardiac MRI: infarct size is an independent predictor of mortality in patients with coronary artery diesease. J Am Coll Cardiol 2005:45:122A,

11. Bello D, Kaushal R, Fieno DS, Goldberger JJ, Shivkumar K, Kadish AH. (P2-45) Cardiac MRI: detection of myocardial infarction in symptomatic patients without coronary artery disease undergoing electrophysiological testing. Heart Rhythm 2005:2:S148.

12. Beohar N, Davidson C, Mehta J, Singhal S, Robbins J, Flaherty JD, Vidovich M, Rapp J, Brodsky A, Rammohan C, Bonow RO, Virmani R. Pathological and functional evaluation of GCSF therapy in a porcine model of myo-cardial infarction. Am J Cardiol 2005;96 (Supp 7A):69H.13. Beohar N, Davidson CJ, Mehta J, Singhal S, Robbins J, Flaherty JD, Vidovich M, Rapp J, Brodsky A, Rammohan C, Bonow RO, Virmani R. Pathological and functional evaluation of GCSF therapy in a porcine model of myocardial infarction. Circulation 2005;112:II-580.

14. Beohar N, Mehta J, Davidson CJ, Singhal S, Lee D, Flaherty JD, Vidovich M, Rapp J, Brodsky A, Rammohan C, Klocke FJ, Wu E, Bonow RO. Dose timing dependent effects of GCSF administration on left ventricular remodeling and global function. J Am Coll Cardiol 2005;45:37A.

15. Beohar N, Robbins J, Cavanaugh BJ, Vidovich M, Yaghmai V, Carr J, Davidson CJ. Quantitative assessment of in-stent dimensions: a comparison of 64 And 16 detector multislice computed tomography to intravascular ultrasound. Am J Cardiol 2005;96 (Supp 7A):193H.

16. Berry JD, Garside D, Cacioppo J, Lloyd-Jones D, Stamler J, Greenland P. Type D personality and 30-year prediction of all-cause and CVD mortality: the Western Electric Study. Circulation 2005;111:e222.

17. Berry JD, Lloyd-Jones DM, Wang R, Greenland P. Social avoidance and the 30-year risk for CHD, CVD, and total death: the Western Electric Study. Circulation 2005; 112: II-803.

18. Bucciarelli-Ducci C, Wu E, Tejedor P, Lee DC, Kansal P, Holly TA, Carr JC, Klocke FJ, Bonow RO. Hypoenhancement on delayed contrast-enhanced MRI following ST-segment elevation myocardial infarction: an alternate approach for evaluating no-reflow. J Cardiovasc Magn Reson 2005;7:43.

19. Burkett DS, Valloppillil SA, Passman RS, Dibs SR, Arora R, Kadish AH, Goldberger JJ. A higher than expected prevalence of AVNRT in patients receiving implantabble defibrillators. Heart Rhythm 2005:2:S163.

20. Dasgupta, A, Passman R. Complications of cardiac rhythm management devices in renal dialysis patients. Heart Rhythm 2005;2:S201

21. De Luca L, Klein L, Udelson JE, Orlandi C, Sardella G, Fedele F, Gheorghiade M. Hyponatremia in patients with heart failure. Am J Cardiol. 2005;96:19L-23L.

22. De Luca L, Orlandi C, Udelson JE, Fedele F, Gheorghiade M. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. Am J Cardiol 2005;96:24L-33L.

23. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, Massie BM, Roland E, Targum S, Collins SP, Filippatos G, Tavazzi L; International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:II-3958-3968.

24. Greenberg B, Abraham W, Albert N, Stough W, Gheorghiade M, O’Connor C, She L, Yancy C, Young J, Fonarow G. Influence of diabetes mellitus on character-istics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure. Circulation 2005;112:II-3826.

25. Feldman MD, Nebeker JR, Virmani R, McKoy JM, Davidson CJ, Hoffman JM, Raisch DW, Belknap SM, West DP, Samore MH, Yarnold PR, Davidson L, Bennett CL. Hypersensitivity reactions in patients with drug eluting stents. J Am Coll Cardiol 2005;45:74A.

26. Feldman T, Herrmann HC, Wasserman HS, Whitlow PL, Block PC, Gray WA, Foster E, St. Goar F. Percutaneous edge-to-edge mitral valve repair using the Evalve clip: current status of the EVEREST

phase I clinical trial. J Am Coll Cardiol 2005;45:359A.

1. Feldman T, Wasserman HS, Herrmann HC, Whitlow PL, Block PC, Gray WA, Foster E, St. Goar F. Edge-to-edge mitral valve repair using the Evalve MitraClip: one year results of the EVEREST phase I clinical

2. trial. Am J Cardiol 2005;96:suppl 7A;49H

3. Fonarow GC, Abraham WT, Albert NA, Gattis W, Gheorghiade M, Greenberg B, O'Connor CM, She L, Yancy CW, Young JB. Does Patient Age Impact the Use of evidence-based heart failure therapies at hospital discharge? A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2005;45: 339A.

4. Fonarow GC, Abraham WT, Albert NA, Gattis W, Gheorghiade M, Greenberg B, O'Connor CM, She L, Yancy CW, Young JB. Can gender-related disparities in the use of evidence-based therapies for heart failure be reduced? A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2005;45: 340A.

5. Fonarow GC, Abraham WT, Albert NA, Gattis W, Gheorghiade M, Greenberg B, O'Connor CM, She L, Yancy CW, Young JB. Impact of evidence-based heart failure therapy use at hospital discharge on treatment rates during follow-up: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure(OPTIMIZE-HF). J Am Coll Cardiol 2005; 45 (Supplement 1): 345A.

6. Fonarow G, Abraham W, Albert N, Gheorghiade M, Greenberg B, O’Connor C, Stough W, Yancy C, Young J, She L. Should beta blocker use at the time of hospital discharge be included as a heart failure performance measure ? A report from OPTIMIZE – HF.. J Card Failure 2005; 11 No.6 (Supplement): S182

7. Ghali J, Smith W, Torre-Amione G, Haynos W, Rayburn B, Amato A, Zhang D, Cowart D, Valentini G, Carminati P, Gheorghiade M. Istaroxime – a novel lusitropic and inotropic agent: results of a phase I-II study. J Card. Failure 2005;11 (Supplement):S152

8. Gheorghiade M, Adams KF, O'Connor CM, Zimmer C, Czerwiec F, John O, Orlandi C. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF). J Am Coll Cardiol 2005;45:145A.

9. Gheorghiade M, Hellkamp AS, Pina IL, Fonarow GC, De Marco T, Pauly DF, Rogers J, DiSalvo T, Butler J, Hare JM, Francis GS, O'Connor CM. Hemodynamic characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.. J Am Coll Cardiol 2005;45:145A.

10. Gheorghiade M, Klein L, Abraham W, Albert N, Greenberg B, O’Connor C, She L, Stough W, Yancy C, Young J, Fonarow G. The relation between admission systolic blood pressure and outcomes in hospitalized patients with heart failure: an OPTIMIZE – HF analysis. J Card. Failure 2005;11 (Supplement):S196.

11. Gheorghiade M, Klein L, Abraham W, Albert N, Greenberg B, O’Connor C, She L, Stough W, Yancy C, Young J, Fonarow G. The relation between admission systolic blood pressure and outcomes in hospitalized patients with heart failure with reduced or preserved systolic function. Circulation 2005;112:II-2832

12. Gheorghiade M, Stough W, O’Connor C, Abraham W, Greenberg B, Young J, Albert N, Yancy C, She L, Fonarow G. Serum sodium concentration and mortality in patients admitted with heart failure: an analysis of OPTIMIZE – HF. J Card Failure 2005;11 (Supplement):S348

13. Hasselblad V, Stough W, Shah M, Lokhnygina Y, Burnett J, Gheorghiade M, Rayburn B, Adams K, Francis G, Califf R. Relation between diuretic dose and outcome in a heart failure population: result of the ESCAPE Trial. J Card. Failure 2005;11 (Supplement):S157

14. Herrmann HC, Wasserman HS, Whitlow PL, Block PC, Gray WA,Rohatgi S, Foster E, St. Goar F, Feldman T. Percutaneous edge-to-edge mitral valve repair using the Evalve MitraClip: initial one year results of the EVEREST phase I clinical trial. Circulation 2005;112:II-520

15. Huang MY, Akhtar T, Sakata Y, Salinger MH, Frohlich TG, McDonough TJ, Koenigsberg DI, Kogan A, Tommaso CL, Sanborn TA, Feldman T. Frequency of off label drug eluting stent use in clinical practice. Am J Cardiol 2005;96: suppl 7A;134H

16. Imai M, Gheorghiade M, Cowart D, Zhang D, Amato A, Carminati P, Sabbah H. Intravenous istaroxime improves left ventricular systolic function in dogs with advanced heart failure without increasing myocardial oxygen consumption. J Card. Failure 2005;11 (Supplement):S95

17. Imai M, Gheorghiade M, Cowart D, Zhang D, Amato A, Carminati P, Sabbah H. Intravenous istaroxime improves left ventricular lusitropic properties in dogs with advanced heart failure. J Card. Failure 2005;11 (Supplement):S238

18. Imai M, Gheorghiade M, Cowart D, Zhang D, Amato A, Sabbah H, Carminati P. Intravenous istaroxime improves left ventricular systolic and diastolic function in dogs with advanced heart failure without increasing myocardial oxygen consumption. Circulation 2005;112:II-2188.

19. James O, Kim HW, Weinsaft J, Wu E, Elliott M, Zenker M, Parker MA, Bonow RO, Judd RM, Kim RJ, Shah DJ. Demonstration and prediction of the potential reversible nature of thinned myocardium by CMR. J Cardiovasc Magn Reson 2005;7:180.

20. Januzzi JL, Sakhuja R, O’Donoghue M, Baggish L, Anwaruddin S, Chae CU, Cameron R, Krauser DG, Tung R, Camargo CA, Lloyd-Jones D. Amino-terminal pro-brain natriuretic peptide strongly predicts one-year mortality in emergency department patients with dyspnea. Circulation 2005; 112: II-753.

21. Johnson NP, Leonard SM, Kansal P, Wu E, Holly TA. Increasing body mass index over a 10-year period in patients referred for perfusion stress testing. J Nucl Cardiol 2005;12:S103.

22. Johnson NP, Leonard SM, Kansal P, Wu E, Holly TA. Relationship of body mass index on exercise capacity and the severity of exercise stress perfusion defects. J Nucl Cardiol 2005;12:S103.

23. Kansal P, Wu E, Leonard SM, Johnson NP, Holly TA. Significance of ventricular ectopy during stress myocardial perfusion imaging. J Nucl Cardiol 2005;12:S103.

24. Kansal P, Zhang Q, Bucciarelli-Ducci C, Simonetti OP, Tejedor P, Holly T, Carr J, Wu E. Marked reduction in acquisition times for velocity quantification using iPAT. J Cardiovasc Magn Reson 2005;7:286.

25. Kim CX, Wu E, Lee DC, Davidson CJ, Bonow RO, Ricciardi MJ. Cardiac MRI within one week of coronary stent implantation is safe. J Cardiovasc Magn Reson 2005;7:301.

26. Lee DC, Tejedor P, Wu E, Chung Y-C, Holly TA, Carr JC, Klocke FJ, Bonow RO. Rapid magnetic resonance infarct imaging by single-shot inversion recovery trueFISP compared to segmented inversion recovery turboFLASH. J Cardiovasc Magn Reson 2005;7:222.

27. Lloyd-Jones DM, Greenland P, Liu K, Detrano R, Burke G, Palmas W, Tracy R, Schreiner P, Otvos J. Association of lipoprotein particle number and size with coronary artery calcification in different ethnicities: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005;111;e197.

28. Lloyd-Jones DM, Wang R, Dyer A, Yan L, Daviglus M, Greenland P. Lifetime risks for cardiovascular or coronary death in African-Americans and whites. Circulation 2005;111:e245.

29. Maganti K, Buchanan K, Huang SL, Tiukinhoy SD, MacDonald RC, McPherson DD. Stability of echogenic immunoliposomes under physiological conditions. J Am Coll Cardiol 2005;45:272A.

30. Mehta RH, Roe MT, Chen AY, Pollack CV Jr, Brindis RG, Ohman EM, Gibler WB, Fintel D, Fraulo ES, Peterson ED. Changing practice for non-ST-segment elevation acute coronary syndromes: trends from the CRUSADE Quality Improvement Initiative from 2002 to 2004. Circculation 2005;112::II-793

31. Moura LM, Zamorano J, Ramos, S Azevedo L, Rocha- Goncalves, F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. Circulation 2005;111:II-688.

32. Ng J, Kadish AH, Goldberger JJ. Effect of double potentials on the estimation of local activation rate using dominant frequency analysis. Circulation 2005;112:II-660

33. Ng J, Kadish AH, Goldberger JJ. Effect of electrogram signal-to-noise ratio on the reliability of dominant frequency analysis in the estimation of activation rate during atrial fibrillation. Circulation 2005;112:II-699

34. Pandya S, Subramanian M, Stock S, Spelsberg T, McCarthy P, Bonow RO, Rajamannan N. Degenerative versus rheumatic mitral valve disease: evaluation of cellular proliferation and osteoblast mediated extracellular matrix production. J Am Coll Cardiol 2005;45:364A

35. Passman R, Singh V, Kapur R, Sharma R, Bennett C. Is Ophthalmic Screening Necessary for Amiodarone-Treated Patients? J Am Coll Cardiol 2005;45:189A

36. Passman R, Subacius H, Ruo B, Kadish A. Impact of shocks on quality of life in patients with non-ischemic dilated cardiomyopathy and implantable cardioverter-defibrillators: results from the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Study. Heart Rhythm 2005;2: S283

37. Persell S, Lloyd-Jones D, Baker D. Implications of changing National Cholesterol Education Program guidelines for the treatment and control of hypercholesterolemia in the United States. Journal of General Internal Medicine 2005;20 (Suppl 1):69.

38. Persell S, Lloyd-Jones D, Baker D. National Cholesterol Education Program risk assessment method and the misclassification of some adults as low-risk. Journal of General Internal Medicine 2005;20 (Suppl 1):69-70.

39. Porter TM, Vaidya SS, Holland CK, Huang SL, MacDonald RM, McPherson DD. Evaluation of backscattered intensity to quantify the destruction rate of echogenic liposomes. J Acoust Soc Am 2005;117:2531.

40. Price MJ, Garcia L, Davidson CJ, McNeil J, Cohen MG, Mathur V, Fearon WF, Low R, Reisman M, Teirstein P. Design and rationale for the Targeted Intra-renal Fenoldopam For Avoidance of Nephropathy (TIFFANY) Trial. Am J Cardiol 2005;96 (Supp 7A):117H.

41. Rajamannan NM, Subramaniam, M, Spelsberg, TC. TGFβ inducible early gene-1 (TIEG1) null mouse induces a cardiac osteoblast phenotype via resident cardiac stem cell differentiation. Circulation 2005;111:II-51.

42. Rashba E, Estes, NAM, Wang P, Schaechter A, Howard A, Zareba W, Couderc JP, Perkiomaki J, Levine J, Kadish AH. Preserved heart rate variability identifies low risk nonischemic cardiomyopathy patients: results from the Definite Trial. Heart Rhythm 2005:2:S54.

43. Reddy M, Robin J, Tiongson J, Hsu J, Passman R. Long-term survival of dialysis patients with implantable cardioverter defibrillators. Circulation 2005

44. Rhew E, McPherson DD, Dyer AR, Kondos GT, Edmundowicz, Sutton-Tyrrell K, Chung A, Smulevitz B, Thompson T, Ramsey-Goldman R. Atherosclerotic markers increase early in systemic lupus erythemastosus. J Am Coll Cardiol 2005;45:416A.

45. Rohatgi S, Wasserman H, Block P, Gray W, Whitlow P, Weigers SE, Sylvestry FE, Foster E, Feldman T, Herrmann HC. Mitral stenosis is not produced by percutaneous edge-to-edge mitral valve repair of mitral regurgitation. Circulation 2005;112:II-520

46. Sandman DN, Carroll TJ, Simonetti OP, O’Hara K, Salanitri J, Cashen T, Pereles FS, Wu E, Carr JC. ECG-triggered dynamic time-resolved magnetic-resonance angiography of the thoracic aorta. J Cardiovasc Magn Reson 2005;7:412.

47. Sharma S, Gerber I, Viloria E, Feldman T, Foster E. Clinically important reduction in mitral regurgitant volume and fraction 6 months following percutaneous edge-to-edge repair. Circulation 2005;112:II-624

48. Sharma S, Gerber I, Viloria E, Feldman T, Foster E. Mitral regurgitation: the need for an integrated approach in clinical trials. Circulation 2005;112:II-339

49. Sharma S, Gerber I, Viloria E, Feldman T, Foster E. Left ventricular function preserved after percutaneous valve repair. Circulation 2005;112:II-341

50. Silvestry FE, Wiegers SE, Herrmann HC, Rohatgi S, Rodrequiez L, Stewart WJ, Homma S, Goyal N, Pulerwitz T, Zunamon A, Hamilton A, Metlino J, Martin J, Krabil K, Wasserman H, Foster E, Feldman T. Echocardiographic guidance of percutaneous repair for mitral regurgitation with the Evalve system: lessons learned from the first 27 cases. J Am Coll Cardiol 2005;45:2A

51. Smith DA, Porter TM, Holland CK, Huang SL, MacDonald RC, McPherson DD. Effect of clinical diagnostic ultrasound pressure amplitude and pulse repetition frequency on echogenic liposome destruction. J Acoust Soc Am 2005;117:2557.

52. Sundaram S, Carnethon M, Shoushtari C, Kadish AH, Goldberger JJ. Parasympathetic effects on the AV node at peak exercise and during recovery. Heart Rhythm 2005:2:S306.

53. Tejedor P, Kansal P, Wu E, Maganti K, Bucciarelli-Ducci C, Lee DC, Carr JC, Holly TA, Bonow RO.Aortic valve area calculation using the continuity equation and cine planimetry: a comparison with echocardiography. J Cardiovasc Magn Reson 2005;7:256.

54. Tejedor P, Wu E, Bucciarelli-Ducci C, Lee DC, Kansal P, Carr JC, Holly TA, Klocke FJ, Bonow RO. Human infarct resorption patterns and long-term ventricular remodeling following myocardial infarctions of varying size. J Cardiovasc Magn Reson 2005;7:26.

55. Tiukinhoy-Laing S, Parikh DS, Huang SL, Martinez J, Kane B, MacDonald RC, McPherson DD. Ultrasound-enhanced in vivo delivery of agents into arterial media using echogenic immunoliposomes. Circulation 2005;112 II-634.

56. Tiukinhoy-Laing S, Huang SL, Parikh DS, Martinez J, Vaidya SS, Holland CK, MacDonald RC, McPherson DD. Ultrasound-facilitated clot lysis using tPA-loaded echo-genic liposomes. Circulation 2005;112:II-634.

57. Ulphani JS, Cain JH, Inderyas F, Gordon D, Gikas PV, Harvey LA, Shade G, Kadish A, Goldberger JJ. Parasympathetic innervation of the ventricles. Circulation 2005;112;II-15

58. Ulphani JS, Cain JH, Inderyas F, Gordon D, Gikas PV, Harvey LA, Nguyen-Tran C, Thordsen S, Shade G, Harris K, Decker R, Arora R, Goldberge JJ, Kadish A. parasympathetic innervations of the posterior left atrium primarily originate in the ligament of Marshall. Circulation 2005;112;II-189

59. Ulphani JS, Kadish AH, Inderyas F, Gordon D, Harris K, Goldberger J, Decker R, Morris A, Zahir S, Ng J, Arora R. Autonomic Innervation of the Pulmonary Veins. J Am Coll Cardiol 2005:45:122A

60. Ulphani JS, Ng J, Gordon D, Morris AR, Shade G, Dibs SR, Arora R, Goldberger JJ, Kadish AH. Frequency gradients during focally driven vs.self-sustained atrial fibrillation in the canine atria. Heart Rhythm 2005:2:S97.

61. Vidovich MI, Lee DC, Wu E, Myers BD, Dravad VP, Davidson CJ. Effects of magnetic resonance imaging and balloon inflation on stability of drug-eluting stent polymer: an in-vitro study. J Cardiovasc Magn Reson 2005;7:336.

62. Wu E, Tejedor P, Lee DC, Bucciarelli-Ducci C, Holly TA, Lloyd-Jones D, Klocke FJ, Bonow RO. Infarct size quantified by contrast-enhanced magnetic resonance imaging predicts ventricular remodeling following an ST-segment elevation myocardial infarction. Circulation 2005;112:II-570

63. Yancy C, Abraham W, Albert N, Stough W, Gheorghiade M, Greenberg B, O’Connor C, She L, Young J, Fonarow G. Defining the natural history and improving quality of care for African Americans hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure. Circulation 2005;112:II-2423.